WithdrawnNot Applicable

Use of Apheretic Technologies in Cardiovascular Disease

Stopped: Funding missing

Italy0

Plain-language summary

To evaluate the effects of H.E.L.P. apheresis on lipid profile, Lp(a) level, and some inflammatory adypocytokines in patients with high cardiovascular risk.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * high Lp(a) not responsive to diet and pharmacological treatment Exclusion Criteria: * heart failure * hepatic failure * renal failure

What they're measuring

Lp(a) reduction

Timeframe: 1 year

Trial details

NCT IDNCT02380534

SponsorUniversity of Pavia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-02-04

View on ClinicalTrials.gov More Dyslipidemia trials